American Renal Associates Holdings Inc. has filed an amended form S-1 with the Securities and Exchange Commission and set the financial terms for its initial public offering. The company will offer 7.5 million shares that it expects to price between $20 and $23 per share, and said it expects to grant an overallotment option for an additional 1.125 million shares. The stock has been approved for listing on the New York Stock Exchange under the ticker symbol “ARA”.
The company wrote in the SEC form that it’s business model, which focuses exclusively on joint ventures, distinguishes it from the other large dialysis providers.
“As of December 31, 2015, on average we held 54% of the interests in our clinics and our nephrologist partners held 46% of the interests. We believe our JV model, combined with a high-quality operational infrastructure, provides our physician partners the independence to make improved clinical decisions so they can focus on maximizing patient care and grow their clinical practices.”